Introduction
Pulmonary aspergillosis can be categorized as invasive, chronic, or allergic (i.e., allergic bronchopulmonary aspergillosis) according to the recent guidelines from the Infectious Diseases Society of America (IDSA) [1] . Chronic forms of pulmonary aspergillosis consist of simple aspergilloma, chronic cavitary pulmonary aspergillosis (CCPA), and chronic necrotizing pulmonary aspergillosis (CNPA) [1] .
CCPA is defi ned as multiple cavities with or without aspergilloma in association with pulmonary and systemic symptoms and an increase in infl ammatory markers. The
Methods

Patients
We reviewed the medical records of all patients with positive serum Aspergillus precipitating antibodies or Aspergillus species isolated from respiratory samples between January 2008 and January 2012 at the Samsung Medical Center, a 1961-bed referral hospital in Seoul, South Korea.
CPA diagnosis was defi nite when it was associated with the following: (i) compatible clinical symptoms, (ii) compatible chest imagery fi ndings, and (iii) a positive serum Aspergillus precipitin test ( Aspergillus fumigatus IgG ELISA kit; IBL International, Hamburg, Germany) or isolation of an Aspergillus species from a respiratory sample (i.e., sputum, transtracheal aspirate, or bronchial aspiration fl uid) ( Table 1 ) [8 -11] . The presence of serum Aspergillus galactomannan antigen was assessed using Platelia Aspergillus antigen kit (Bio-Rad, Hercules, CA, USA). Not all patients were tested for serum Aspergillus antigen, due to the fact that the clinical usefulness of this test is controversial in patients with non-invasive forms of aspergillosis [12] .
Patient management and data collection
In Korea, voriconazole has not been approved for the initial treatment of CPA, patients were initially treated with oral itraconazole (200 mg twice a day, itraconazole capsule, Janssen Korea Ltd, Seoul, Korea) for at least 6 months. After treatment, laboratory examinations including white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), as well as chest computed tomography (CT). In vitro drug susceptibility tests of itraconazole against Aspergillus isolates and measurement of blood levels of antifungal agents were not performed.
Data were collected, in an anonymous manner, on standardized forms, with follow-up data was last obtained on 30 August 2012. The Institutional Review Board at Samsung Medical Center approved the study protocol. Informed consent was waived because of the retrospective nature of the study.
Treatment outcomes and survival
Clinical improvement was defi ned as the disappearance of more than half of the symptoms noted at the initial evaluation and during follow-up visits. Radiological improvement was defi ned as the partial or complete disappearance of fi ndings thought at fi rst to be associated with CPA, although abnormalities related to the lung disease that contributed to CPA development could persist [8] . Favorable response was defi ned as symptomatic improvement with radiologic improvement or symptomatic improvement despite no defi nite radiologic alterations after completion of at least 6 months of antifungal therapy. Unfavorable response was defi ned as worsening or no symptomatic improvement regardless of radiologic change or treatment duration, or discontinuation of antifungal therapy for any other reason prior to 6 months.
Statistical analysis
All data are presented as medians and interquartile ranges (IQR) for continuous variables and as numbers (percentages) for categorical variables. The data were compared using the Mann-Whitney U test for continuous variables and a Chi-squared or Fisher ' s exact test for categorical variables. All statistical analyses were performed using PASW 20.0 (SPSS Inc., Chicago, IL, USA) and a two-sided P Ͻ 0.05 was considered to indicate statistical signifi cance.
Results
Patient characteristics
A total of 119 patients with clinically suspected pulmonary aspergillosis who had positive precipitating serum Aspergillus antibodies or Aspergillus species isolated from The most common etiologic agent were members of the Mycobacterium avium-intracellulare complex ( n ϭ 18), followed by M. abscessus-massiliense complex ( n ϭ 9), M. kansasii ( n ϭ 4), and M. xenopi ( n ϭ 1).
Other underlying lung conditions included chronic obstructive pulmonary disease (COPD) ( n ϭ 35; 50%), bronchiectasis ( n ϭ 18; 26%), previous thoracic surgery ( n ϭ 13; 19%), and a history of pneumothorax ( n ϭ 10; 14%). Only a small percentage of patients had underlying systemic diseases which did not require immunosuppressive agents or corticosteroids.
Chest CT fi ndings
Chest CT fi ndings in patients with CPA are shown in Table 3 . One or more pulmonary cavities with paracavitary infi ltrates, including pleural thickening ( n ϭ 70, 100%) or parenchymal infi ltrate ( n ϭ 67, 96%) were the most common CT abnormalities. The most common location of cavitary lesions was the right upper lobe ( n ϭ 31, 44%). The median size of cavities was 48.5 mm (IQR, 39.0 -61.5 mm) and mycetomas were observed inside the cavitary lesions in 25 patients (36%).
Laboratory fi ndings
The results of laboratory tests for infl ammatory markers and microbiological studies for Aspergillus are shown in Table 4 . Levels of infl ammatory markers such as CRP respiratory samples were identifi ed during the study period. A total of 49 patients with simple aspergilloma ( n ϭ 29), allergic bronchopulmonary aspergillosis ( n ϭ 8), limited clinical data ( n ϭ 8), and immunocompromised status ( n ϭ 4), who had hematologic malignancies, recent chemotherapy, and liver transplantations were excluded from the investigation. Consequentially, 70 patients with newly diagnosed CPA were the basis of this study.
Clinical characteristics of the study patients are shown in Table 2 , which indicated that the median age was 55 years (IQR, 46 -68 years), 51 (73%) were males, 45 (64%) were current or ex-smokers and the median body mass index (BMI) was 18.0 kg/m 2 (IQR, 16.0 -19.6 kg/m 2 ). All patients presented with chronic pulmonary or systemic symptoms, such as purulent sputum ( n ϭ 65, 93%), cough ( n ϭ 63, 90%), hemoptysis ( n ϭ 30, 43%) and weight loss ( n ϭ 16, 23%). The median duration of symptoms prior to diagnosis was 4 months (IQR, 3 -6 months).
All patients had at least one underlying lung disease, with tuberculosis being the most common ( n ϭ 57, 81%). Pulmonary disease caused by nontuberculous mycobacteria 
Antifungal therapy response and outcomes of patients with CPA
Clinical, radiological, and laboratory responses to antifungal treatment are summarized in Table 5 . All but one patient ( n ϭ 69; 99%) were treated with oral itraconazole with the remaining patient was initially treated with oral voriconazole. The median duration of treatment for all patients was 6.4 (IQR, 6.0 -8.9) months, which included 54 (77%) who received antifungal therapy for at least 6 months and the remaining 16 (23%) patients being treated for than 6 months. Antibiotics against NTM, as well as antifungal therapy were administered in 15 patients with concurrent active NTM lung disease. Rifampin was the drug of choice for 10 patients with M. avium-intracellulare complex ( n ϭ 8), M. kansasii ( n ϭ 1), and M. xenopi ( n ϭ 1) lung disease. Patients with lung infections caused by M. abscessus-massiliense complex were treated with amikacin, cefoxitin, and clarithromycin without rifampin [13, 14] . Clarithromycin was administered with itraconazole in 14 patients with concurrent active NTM lung disease.
As shown in Table 5 , treatment response rates were 73% based on alleviation of symptoms and 44% based on chest CT fi ndings (Fig. 1) . Of the 69 patients whose blood tests were available, CRP and ESR levels decreased in 57 (83%) and 53 (77%) samples, respectively. Follow-up serum Aspergillus precipitin antibody data were available for 53 patients and the results of fungal culture in cases of 47 patients. Serum Aspergillus precipitin antibody titers decreased in 33 (62%) patients and fungal culture negative conversion occurred in 12 (67%) of 18 patients who had positive culture results prior to treatment.
Finally, a total of 44 (62%) patients had favorable responses to antifungal treatment. However, fi ve of these patients (11%) relapsed with worsening of symptoms after a median of 9.2 (IQR, 4.7 -16.8) months causing their retreatments with itraconazole. Of the remaining 26 patients (38%) who did not respond favorably to antifungal treatment, 16 were prematurely taken off the antifungal treatment due to adverse reaction ( n ϭ 7), death ( n ϭ 5), and lack of follow-up ( n ϭ 4). In addition, there was no change ( n ϭ 4) or worsening ( n ϭ 6) of symptoms despite the fact that these 10 patients had been on treatment for at least 6 months. Adjunctive surgical resection was performed to manage massive hemoptysis in six patients (9%) at a median of 5 (IQR, 4.5 -6.0) months after diagnosis which included bronchial arterial embolizations prior to surgery. Pulmonary resections included lobectomy ( n ϭ 2), segmentectomy ( n ϭ 2), and completion pneumonectomy ( n ϭ 1). There were no major complications associated with surgery.
Death occurred in 10 patients (14%) involving three in the favorable response group and seven in the unfavorable response group with their negative outcomes attributed to respiratory failure. The median duration between diagnosis of CPA and death of 10 patients were 12.4 (IQR, 2.5 -17.0) months.
Adverse reactions to antifungal therapy
Adverse reactions associated with antifungal agents were observed and were primarily associated with gastrointestinal problems such as nausea ( n ϭ 11; 16%), anorexia ( n ϭ 10; 14 %), and diarrhea ( n ϭ 8; 11%). Both hepatotoxicity (a liver transaminase level of Ն 120 IU/L) and generalized edema was observed in fi ve (7%) patients. A fatal adverse reaction with severe QT prolongation was noted in one patient. Overall, seven patients discontinued treatment as a result of their adverse reactions and the median treatment duration of these individuals was 2.3 months (IQR, 1.7 -3.3 months).
Comparisons between patients who had favorable or unfavorable treatment responses
We additionally evaluated the differences in clinical, radiologic, and laboratory data and outcomes between CPA patients in the favorable and unfavorable response groups (Table 6 ). Patients with favorable responses were younger ( P ϭ 0.009) and had lower initial ESR levels ( P ϭ 0.039) compared with patients with unfavorable responses. The proportion of co-morbidities such as NTM disease ( P ϭ 0.041) and chronic renal failure ( P ϭ 0.047) were signifi cantly higher in patients with unfavorable responses. However, there was no signifi cant difference in symptoms and radiologic fi ndings between the two groups. Finally, mortality in the unfavorable response group was high compared with the favorable response group ( P ϭ 0.032).
Discussion
The objective of this retrospective study was to describe the clinical characteristics and treatment responses to oral itraconazole in CPA cases. We found that NTM lung disease, as well as pulmonary tuberculosis was the important underlying condition of CPA and about two-thirds of patients with CPA had a favorable response to itraconazole treatment for approximately 6 months.
Although the optimal therapeutic regimen and treatment duration have not been established, previous studies have reported good responses to the use of itraconazole in the treatment of CPA [15 -20] . De Beule et al . reported a marked improvement or cure in 66% of CNPA patients treated with itraconazole [15] . In the series by Dupont, 14 CNPA patients were treated with itraconazole for 2 -7 months of which seven were cured and six improved signifi cantly [16] . In the current study, we also observed favorable responses to itraconazole treatment in approximately two-thirds of patients with CPA. Although responses rates may differ based on the duration of the treatment, as well as the defi nition of responsiveness, these results support current recommendations from IDSA that itraconazole be used as an initial CPA treatment [1] .
The most common underlying diseases that predisposed patients to CPA included pulmonary tuberculosis and chronic obstructive pulmonary disease [21] . However, concurrent active or prior NTM are considered important underlying conditions [3, 4, 22] . In addition, patients with a history of pulmonary infection caused by NTM may have a higher rate of subsequent CPA compared to those with a history of pulmonary tuberculosis [3] . In our study, 15 patients with CPA had concurrent active NTM lung disease, which suggested that Aspergillus and NTM can coinfect. Since Aspergillus co-infection in patients with NTM disease is important, early microbiological testing should be considered in patients with progressively worsening symptoms or low response to treatment of underlying lung disease accompanying cavitary lesions. This early laboratory intervention would provide a rapid and precise diagnosis and could improve treatment outcomes.
There are some limitations to this study. First, it was unclear whether these patients had culture-confi rmed prior pulmonary tuberculosis despite the fact this was reported as the most common underlying lung disease. Patients with acid-fast bacilli-positive sputum or those displaying chest radiographic fi ndings that suggested active tuberculosis had generally been presumed to have pulmonary tuberculosis and were treated empirically with antituberculous drugs [14, 23] . Second, the defi nition of favorable response was not particularly precise in our study. We could not offer the objective parameters such as the improvement of BMI in this retrospective study. In addition, attributing symptom changes to CPA could not be accurately measured in patients with concurrent NTM lung disease after antifungal treatment, as well as anti-NTM therapy. Third, median follow-up durations of 13 months may not be suffi cient to evaluate treatment outcomes. The relatively lower mortality rate of 14% in the current study (compared to data reported previously) may have been infl uenced by the relatively short-term follow-up. Therefore, long-term follow-up studies of the prognosis of CPA patients who received long-term antifungal therapy may be required. Fourth, since this is a retrospective analysis, data pertaining to follow-up laboratory tests were available, which may not allow for accurate examination of the association between microbiological response and antifungal therapy. Lastly, since 15 patients had concurrent active NTM disease when CPA was diagnosed, the treatment outcomes of CPA may have been infl uenced by the progression or improvement of the underlying pulmonary condition rather than antifungal [25] . These could have in turn contributed to higher unfavorable treatment response in patients with concurrent NTM lung disease.
In conclusion, pulmonary tuberculosis and NTM lung disease were the important underlying conditions of CPA. Treatment with oral itraconazole for approximately 6 months was moderately effective in treating CPA; however, development of a more effective treatment is necessary. Thus, further evaluation in a prospective, randomized controlled study is required.
